Form 8-K - Current report:
SEC Accession No. 0001013762-25-002718
Filing Date
2025-03-26
Accepted
2025-03-26 16:10:25
Documents
15
Period of Report
2025-03-25
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ea023575401-8k_abpro.htm   iXBRL 8-K 31420
2 PRESS RELEASE, DATED MARCH 25, 2025 ea023575401ex99-1_abpro.htm EX-99.1 5621
  Complete submission text file 0001013762-25-002718.txt   258654

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE abp-20250325.xsd EX-101.SCH 3854
4 XBRL DEFINITION FILE abp-20250325_def.xml EX-101.DEF 26755
5 XBRL LABEL FILE abp-20250325_lab.xml EX-101.LAB 36995
6 XBRL PRESENTATION FILE abp-20250325_pre.xml EX-101.PRE 25379
17 EXTRACTED XBRL INSTANCE DOCUMENT ea023575401-8k_abpro_htm.xml XML 5990
Mailing Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013
Business Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013 248-890-7200
Abpro Holdings, Inc. (Filer) CIK: 0001893219 (see all company filings)

EIN.: 871013956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41224 | Film No.: 25773273
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)